Comparative effectiveness of diet alone and diet plus metformin treatment on omentin levels in type 2 diabetes patients with nonalcoholic fatty liver disease: a prospective randomized trial

Arslan, Ibrahim; Ulaş, Turgay; Karakaş, Ekrem; Demir, Mehmet; Eren, Mehmet Ali; Torun, Aysenur; Sabuncu, Tevfik

doi:10.18054/pb.v119i1.4180

Cited by 7 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, according to some studies, it is possible to regulate omentin-1 levels in these patients. It has been observed that weight loss can increase levels of this adipokine in obese patients with T2DM [ 74 ]. It has also been noted that omentin-1 levels are increased in pre-diabetic states, suggesting that this adipokine may increase insulin sensitivity, and its secretion is increased as a defense mechanism in the early stages of glucose intolerance [ 75 ].…”

Section: Biomoleculesmentioning

confidence: 99%

Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus

Ruszała

Niebrzydowska

Pilszyk

et al. 2021

IJMS

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is one of the most common metabolic diseases in pregnant women. Its early diagnosis seems to have a significant impact on the developing fetus, the course of delivery, and the neonatal period. It may also affect the later stages of child development and subsequent complications in the mother. Therefore, the crux of the matter is to find a biopredictor capable of singling out women at risk of developing GDM as early as the very start of pregnancy. Apart from the well-known molecules with a proven and clear-cut role in the pathogenesis of GDM, e.g., adiponectin and leptin, a potential role of newer biomolecules is also emphasized. Less popular and less known factors with different mechanisms of action include: galectins, growth differentiation factor-15, chemerin, omentin-1, osteocalcin, resistin, visfatin, vaspin, irisin, apelin, fatty acid-binding protein 4 (FABP4), fibroblast growth factor 21, and lipocalin-2. The aim of this review is to present the potential and significance of these 13 less known biomolecules in the pathogenesis of GDM. It seems that high levels of FABP4, low levels of irisin, and high levels of under-carboxylated osteocalcin in the serum of pregnant women can be used as predictive markers in the diagnosis of GDM. Hopefully, future clinical trials will be able to determine which biomolecules have the most potential to predict GDM.

show abstract

Section: Biomoleculesmentioning

confidence: 99%

Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus

Ruszała

Niebrzydowska

Pilszyk

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…However, some studies showed a decrease in omentin plasma concentration with a LCD, despite weight loss and improved fasting glucose [16, 18, 35]. We observed that 2 weeks of a VLCD did not affect omentin plasma concentrations and gene expression [18].…”

Section: Discussionmentioning

confidence: 87%

“…A growing number of studies examining omentin have generated contradictory findings. Some reported that omentin plasma concentration increased after a low-calorie diet (LCD) [12, 15], while others revealed that these diets lead to a reduction in omentin plasma concentration [16, 17]. There was no change in omentin plasma concentration in response to a very low-calorie diet (VLCD) [18], soybean oil [19], or sesame oil [20].…”

Section: Introductionmentioning

confidence: 99%

Does Dietary Intake Impact Omentin Gene Expression and Plasma Concentration? A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Background: Omentin is an adipokine with anti-inflammatory and insulin-sensitizing effects that can play a protective role against cardiovascular disease and diabetes. The aim was to systematically review and summarize the existing evidence on the association between overall dietary intake and omentin gene expression and circulation. Summary: A literature search was conducted in PubMed, Scopus, and Web of Science up to September 2019. Of the 1,940 retrieved articles, 20 relevant studies were included, 6 of which were observational, 11 were clinical trials in humans, and 3 were animal studies. Four randomized controlled trials (RCTs) had a high risk of bias (RoB), 1 had “some concerns”, and 2 had a low RoB. Among the nonrandomized studies with comparators, 4 had a serious RoB and 2 had a moderate RoB. In the experimental animal studies with a moderate RoB, conflicting results for omentin serum concentration were found for high-fat and low-fat diets. A high-fat diet (HFD) was shown to reduce omentin gene expression in one animal study. In the observational studies, omentin serum concentration was reduced by Ramadan fasting and saturated fatty acid (SFA) intake, and an increase in omentin gene expression was observed with monounsaturated fatty acid (MUFA) intake. There was no association of dietary inflammatory index (DII), macronutrient intake, or total calorie intake with omentin plasma concentrations. In the human interventional studies, omentin plasma concentration increased with a long-term low-calorie, low-fat diet (LFD), and no change was seen with a HFD or a short-term low-calorie diet (LCD). Key Messages: It seems that a long-term diet with a lower fat content and a balanced distribution of fatty acids, i.e., a higher MUFA and lower SFA intake, may effectively increase omentin plasma concentration, possibly via improved insulin resistance and reduced inflammation, but more research is needed to confirm or refute this.

show abstract

“…Of these, 22 studies were selected for this meta-analysis ( Figure 1 ). 18 – 39 The characteristics of the included studies are summarized in Table 1 . 18 – 39 A total of 1698 patients with NAFLD were included in the 22 studies, with a mean age of 44.3 years and a median follow-up time of 12–96 weeks.…”

Section: Resultsmentioning

confidence: 99%

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis

et al. 2023

View full text Add to dashboard Cite

Objective To undertake a network meta-analysis to compare the relative efficacy of a dual peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonist, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin in patients with non-alcoholic fatty liver disease (NAFLD). Methods Electronic databases, including Embase®, PubMed® and The Cochrane Library, were searched systematically for eligible studies from inception to 20 July 2022. Randomized controlled trials (RCTs) that investigated aspartate aminotransferase, alanine aminotransferase (ALT) and triglyceride levels were considered for inclusion. Data were extracted using a standardized data collection table. A network meta-analysis was performed. Relative risk and 95% confidence interval were calculated for continuous data and I2 was used to assess the heterogeneity of studies. Results A total of 22 RCTs involving 1698 patients were eligible for inclusion in the analysis. Both direct analysis and indirect analysis showed that saroglitazar was significantly superior to GLP-1RAs in improving ALT levels. Metformin improved ALT levels, but the effect was not as good as saroglitazar. Conclusion Saroglizatar was the most effective drug for improving NAFLD. INPLASY registration number: INPLASY202340066

show abstract

Comparative effectiveness of diet alone and diet plus metformin treatment on omentin levels in type 2 diabetes patients with nonalcoholic fatty liver disease: a prospective randomized trial

Cited by 7 publications

References 18 publications

Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus

Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus

Does Dietary Intake Impact Omentin Gene Expression and Plasma Concentration? A Systematic Review

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis

Contact Info

Product

Resources

About